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://dSummary
Respiratory viruses that emerge in the human population may cause high morbidity and mortality, as well as
concern about pandemic spread. Examples are severe acute respiratory syndrome coronavirus (SARS-CoV)
and novel variants of influenza A virus, such as H5N1 and pandemic H1N1. Different animal models are
used to develop therapeutic and preventive measures against such viruses, but it is not clear which are most
suitable. Therefore, this review compares animal models of SARS and influenza, with an emphasis on non-
human primates, ferrets and cats. Firstly, the pathology and pathogenesis of SARS and influenza are
compared. Both diseases are similar in that they affect mainly the respiratory tract and cause inflammation
and necrosis centred on the pulmonary alveoli and bronchioles. Important differences are the presence ofmulti-
nucleated giant cells and intra-alveolar fibrosis in SARS and more fulminant necrotizing and haemorrhagic
pneumonia in H5N1 influenza. Secondly, the pathology and pathogenesis of SARS and influenza in man
and experimental animals are compared. Host species, host age, route of inoculation, location of sampling
and timing of sampling are important to design an animal model that most closely mimics human disease.
The design of appropriate animal models requires an accurate pathological description of human cases, as
well as a good understanding of the effect of experimental variables on disease outcome.
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In man, viral infections causing respiratory disease
have been known for many years. Every now and
then such viruses may cause epidemics involving large
groups of people or even pandemics with worldwide
spread. At the end of the last century and at the begin-
ning of this century zoonotic viruses emerged that were
of serious risk for the human population: severe acute
respiratory syndrome (SARS) caused by SARS coro-
navirus (CoV), highly pathogenic avian influenza
(HPAI) virus H5N1 and pandemic influenza virus
A(H1N1)pdm09 (pH1N1). Both SARS-CoV and
influenza A viruses cause respiratory disease that may
lead to severe and even fatal cases of pneumonia. The
course and outcome of these infections are related to
their pathogenesis, which can be explored by
describing and comparing pathology, virology and ge-
nomics. Understanding the pathogenesis of SARS and
influenza is valuable for development of therapeutic
and preventive strategies. Since the pathology of acute
human fatal cases of SARS and influenza is rarely
described, there is a need for animal models to provide
information about the early stages of the disease. Addi-
tionally, pathological descriptions of human cases with
uncomplicated viral pneumonia are sparse because pa-
tients have multiple therapeutic interventions and sec-ondary co-infections thatmay alter the pathology.This
review focuses on the pathology and pathogenesis of
SARS-CoV and influenza A virus infections, not only
comparing the two viruses, but also comparing the pa-
thology of these virus infections in experimental ani-
mals to that in man (van den Brand, 2013).Severe Acute Respiratory Syndrome
Coronavirus
Background
In November 2002, there was an unusual epidemic of
severe pneumonia of unknown cause in Guangdong
province in southern China that spread rapidly across
theworld, peaked in the first half of 2003 and ended by
July 2003 (Xu et al., 2004). A total number of 8,096
probable cases were reported by the World Health
Organization (WHO), which resulted in 774 deaths,
a fatality rate of almost 9.6% (WHO, 2003). A novel
coronavirus, SARS-CoV, was proven to be the cause
of the disease by fulfilling Koch’s postulates (Drosten
et al., 2003; Fouchier et al., 2003; Kuiken et al., 2003a).
SARS is a zoonotic disease and bats are believed to
be the reservoir host of this virus (Li et al., 2005b).
Masked palm civet cats and raccoon dogs, which
are kept and sold at so-called Chinese wet-markets
Animal Models of SARS and Influenza 85(markets selling live poultry, fish and exotic animals
for human consumption), have provided transmission
of the virus to man (Guan et al., 2003;Webster, 2004).
In 2005, horseshoe bats were identified as a natural
reservoir for a group of coronaviruses closely related
to SARS-CoV with approximately 88e92% homol-
ogy by genome sequences (Lau et al., 2005; Li et al.,
2005b). SARS is spread by close person-to-person
contact through droplet transmission or excretions
(Peiris et al., 2003b), as was demonstrated in a hospi-
tal where virus spread due to over-crowding and poor
ventilation (Wong et al., 2005), and later also by
airborne transmission in a private residential complex
in Hong Kong (Yu et al., 2005).The Pathology of Severe Acute Respiratory Syndrome in Man
Gross pathology of the respiratory tract demonstrates
a variable degree of consolidation, oedema, haemor-
rhage and congestion of the lungs, and pleural effusion
in the thoracic cavity (Ding et al., 2003; Nicholls et al.,
2003; Tse et al., 2004). The histopathology of SARS is
characterized by diffuse alveolar damage (DAD). The
stage of DAD is related to the duration of the illness
and may be divided into an exudative phase, a
proliferative phase and a fibrotic phase. Patients in
the initial 10 days of the disease demonstrate an
exudative phase, with necrosis of alveolar epithelial
cells, intraluminal oedema, fibrin exudation, hyaline
membrane formation, haemorrhage and infiltrates
with inflammatory cells such as monocytes or
macrophages, lymphocytes and neutrophils into the
alveolar wall and lumina (Ding et al., 2003; Nicholls
et al., 2003; Hsueh et al., 2004; Shieh et al., 2005).
There is necrosis of the bronchiolar and bronchial
epithelium with infiltration of monocytes,
lymphocytes and neutrophils into the bronchial wall
(Ding et al., 2003; Franks et al., 2003). In the
proliferative phase, after 10e14 days, there is less
epithelial damage with interstitial and alveolar
fibrosis, bronchiolitis obliterans organizing
pneumonia (BOOP) and regeneration that is
characterized by type II pneumocyte hyperplasia
(Franks et al., 2003; Cheung et al., 2004; Shieh et al.,
2005; He et al., 2006). Large multinucleated
cells composed of macrophages or pneumocytes
are frequently observed and atypical enlarged
pneumocytes with large nuclei, amphophilic
granular cytoplasm and prominent nucleoli are seen
(Franks et al., 2003; Nicholls et al., 2003; Tse et al.,
2004). In the fibrotic phase after 14 days interstitial
thickening is described with mild to moderate
fibrosis and BOOP-like pattern and only few inflam-
matory cells (mainly histiocytes and lymphocytes)
(Cheung et al., 2004; Tse et al., 2004). Other featuresare haemophagocytosis, squamous metaplasia
(Nicholls et al., 2003) and fibrin thrombi in vessels
(Ding et al., 2003).
Extrarespiratory changes are present that differ in
severity of the pathology and vary with the duration
of illness. The lymphoid system demonstrates haemo-
phagocytic syndrome and lymphoid depletion or ne-
crosis in lymph nodes and white pulp of the spleen
(Ding et al., 2003; Gu et al., 2005). The pathology in
other organs is characterized by acute tubular
necrosis in the kidneys, oedema and degeneration of
neurons in the central nervous system, myofibre
necrosis and atrophy in skeletal muscles, necrosis
and infiltration of lymphocytes and monocytes in
the adrenal gland, destruction of follicular epithelial
cells in the thyroid gland, germ cell destruction in
the testes and oedema and atrophy of myocardial
fibres in the heart (Ding et al., 2003). In the intestinal
tract there is depletion of mucosal lymphoid tissue
(Leung et al., 2003; Gu and Korteweg, 2007).Animal Models for Human Severe Acute Respiratory Syndrome
Many different animal species are found to be suscepti-
ble to SARS-CoV and subsequently demonstrate viral
replication and disease: non-human primates, cats, fer-
rets,mice, pigs, chickens, hamsters, guineapigs and rats
(Martina et al., 2003;Wentworth et al., 2004;Weingartl
et al., 2004b; Liang et al., 2005; Roberts et al., 2006;
Rockx et al., 2009). Experimental SARS-CoV infection
in each of these species has been performed for a variety
of purposes and resembles the clinical and pathological
characteristics of SARS in man to a variable degree.
Mice and hamsters have been used in studies of patho-
genesis and screening for vaccines and antiviral drugs
(Yang et al., 2004b; Roberts et al., 2005). Young mice
show viral replication that is not accompanied by
substantial inflammation in the lungs; in contrast, old
BALB/c mice develop clinical illness with weight loss
and histopathological changes characterized by
pneumonitis and bronchiolitis (Wentworth et al.,
2004; Roberts et al., 2005). Non-human primates,
such as cynomolgus macaques, African green monkeys
and rhesusmacaques, have been used to evaluate treat-
ment and for pathogenesis studies (Gao et al., 2003;
Kuiken et al., 2003a; Bukreyev et al., 2004; McAuliffe
et al., 2004; Rowe et al., 2004; Li et al., 2005a; Qin
et al., 2006). Cats and ferrets have been used to
evaluate the pathogenesis, while ferrets have also
been used for vaccination studies (Martina et al.,
2003; Weingartl et al., 2004a). Although different
animal species are susceptible to SARS-CoV infection,
no animal model has been established in which all as-
pects of the severe human disease are replicated accu-
rately. In this review, SARS-CoV infection is
Fig. 1. Lesions in the bronchioles and alveoli of cats, ferrets and cynomolgus macaques infected experimentally withH5N1 influenza virus
and SARS-CoV are characterized byDAD and bronchiolitis. HE. Bars, 50 mm (A, E, I and J). Bars, 20 mm (BeD, FeH,Kand L).
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Animal Models of SARS and Influenza 87described in non-human primates (cynomolgus ma-
caques and African green monkeys [AGMs]) and car-
nivores (ferrets and cats) (Fouchier et al., 2003; Kuiken
et al., 2003a;Martina et al., 2003;McAuliffe et al., 2004).
Non-Human Primates. In cynomolgus macaques the
age of the animals influences the pathology after
SARS-CoV infection. The severity of the lesions in
aged cynomolgus macaques infected with SARS-
CoV ismore extensive than in young-adultmacaques,
including severe oedema with hyaline membrane for-
mation and syncytia (Smits et al., 2010) (Fig. 1).
Young-adult AGMs develop more severe lesions
from SARS-CoV infection than young-adult cyno-
molgus macaques (Fouchier et al., 2003; Kuiken
et al., 2003a; McAuliffe et al., 2004; Smits et al.,
2011). By gross pathology, the percentage of affected
lung tissue is higher in AGMs than in cynomolgus
macaques and is characterized by multifocal
consolidation. By histopathology, there is acute
exudative DAD characterized by necrosis of alveolar
epithelium, moderate multifocal hypertrophy and
hyperplasia of type II pneumocytes, variable
intraluminal oedema and exudate sometimes with
hyaline membrane formation, mild multifocal
necrosis and regeneration of bronchiolar epithelium,
and sometimes intraluminal syncytial cells or mild
multifocal tracheobronchoadenitis (inflammation of
the submucosal glands of the trachea and bronchi).
These pulmonary lesions are significantly more
severe in young-adult AGMs than in young-adult
cynomolgus macaques. However, the character of
the pulmonary lesions is similar, except that young-
adult AGMs show hyaline membranes and young-
adult cynomolgus macaques do not (Table 1).
Carnivores. Cats and ferrets infected with SARS-
CoV develop similar lesions in the respiratory tract
as people, macaques and AGMs (Table 1, Fig. 1).
In the lungs of cats there is a multifocal, mild to
moderate exudative DAD and multifocal mild to
moderate tracheobronchoadenitis. In ferrets infected
with SARS-CoV, the resultant DAD is more exten-
sive and severe in ferrets than in cats, and includes
alveolar oedema. Another difference is that cats
develop tracheobronchoadenitis, while ferrets do
not.Comparative Pathology
When the pathological features of SARS in man and
the above-mentioned laboratory animal species are
compared, there are both similarities and differences
in localization, character and severity (Table 1)
(Ding et al., 2003; Franks et al., 2003; Gu et al.,2005; Shieh et al., 2005). Firstly, the localization of
the lesions is similar among all species: lesions are
centred on alveoli and bronchioles. Additionally,
AGMs, young-adult macaques and cats have lesions
in the submucosal glands of trachea and bronchi
that are not seen in man. Secondly, the character of
the lesions is similar among all species; these
characteristics are epithelial necrosis, infiltration of
inflammatory cells and type II pneumocyte
hyperplasia. Additionally, syncytia and hyaline
membranes are present in lesions of man, aged
macaques and AGMs. Thirdly, the severity of the
lesions among species can be divided into two
groups. Man, aged macaques and AGMs have
severe DAD, characterized by oedema, fibrin and
hyaline membranes. Young-adult macaques, cats
and ferrets have milder DAD demonstrating a more
multifocal distribution and lacking the above-
named features.
The development of fibrosis in the late stages of
human cases of SARS may be related to several fac-
tors. Firstly, there is irreversible damage to the pneu-
mocytes, which therefore fail to re-epithelialize the
alveolar walls. Instead, the denuded basement mem-
brane is repaired by fibrosis. Secondly, there may be
a specific epithelial sensitivity to interferon (IFN)-g:
lung epithelial cells are more responsive to IFN-g-
induced damage than fibroblasts during SARS-
CoV infection. Thirdly, there may be a T-helper
(Th)1-dominant immune-mediated cell death,
which may favour the damage to infected alveolar
epithelial cells over damage to non-infected fibro-
blasts, leaving the latter relatively intact. This would
mean destruction of the epithelial layer, a basis for
stimulation of fibroblasts for repair (Theron et al.,
2005). Fourthly, there may be Fas-mediated
apoptosis of human epithelial cells, while lung fibro-
blasts are protected and are also not infected by
SARS-CoV (Coulter et al., 2002; Tanaka et al.,
2002). The importance of the previously-mentioned
factors for fibrosis in SARS is not clear and needs
further investigation.
There are several differences that one has to take
into account when comparing the lesions of SARS in
man with those in experimentally infected laboratory
animals (Table 1). These include differences in the
route of entry of the virus, the dose of the virus on entry,
the physiology of the respiratory tract, the susceptibil-
ity to SARS-CoV infection, the tropism of the virus
and the immune response. Furthermore, one should
realize that most pathological descriptions of human
SARS involve people who have been hospitalized for
an extended period and have undergone multiple in-
terventions; there are only a limited number of descrip-
tions of acute fatal human cases without intervention.
Table 1
Histopathology, virus antigen expression and ACE2 antigen expression in different species infected with SARS-CoV
Species Age Histological lesions
Alveoli Bronchioles Bronchi Interstitium Trachea
Epithelial
necrosis
Oedema Hyaline
membranes
Inflammation Syncytial
cells
Type II pneumocyte
hyperplasia
Epithelial
necrosis
Inflammation Epithelial
necrosis
Inflammation Perivascular/
peribronchiolar
cuffing
Tracheobronchoadenitis Epithelial necrosis Inflammation
Human + + + + + + + +     
Macaque* Young-adult + +  +  + + +   + +  
Aged + + + + + + + +   +   
AGM† Young-adult + + + + + + + +   + +  
Ferret Young-adult + +  +  + + +   +   
Cat Young-adult +   +  + + +    +  
Species Age Virus antigen expression ACE2 antigen expression
Type I
pneumocytes
Type II
pneumocytes
Alveolar
macrophages
Bronchiolar
epithelial cells
Bronchial
epithelial cells
Tracheal
epithelial cells
Serous cells
of submucosal
glands
Type I
pneumocytes
Type II
pneumocytes
Alveolar
macrophages
Bronchiolar
epithelial
cells
Bronchial
epithelial
cells
Pulmonary
goblet cells
Tracheal
epithelial cells
Serous cells of
submucosal
glands
Human + + + + + +  + + + + +  + +
Macaque* Young-adult + + + + +    + + + N N N N
Aged + + + + +    + + + N N N N
AGM† Young-adult + + + +  +   + N N N N N N
Ferret Young-adult  + +      + + + +  + +
Cat Young-adult + + + + + + + + + + + + + + +
N, not done.
*Cynomolgus macaque.
†African green monkey.
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Table 2
Histopathology, virus antigen expression and virus attachment in different species infected with different influenza viruses
Virus and species Histological lesions
Alveoli Bronchioles Bronchi Interstitium Trachea Nose
Epithelial
necrosis
Oedema Hyaline
membranes
Inflammation Type II
pneumocyte
hyperplasia
Epithelial
necrosis
Inflammation Epithelial
necrosis
Inflammation Perivascular/
peribronchiolar
cuffing
Tracheobronchoadenitis Epithelial
necrosis
Inflammation Epithelial necrosis Inflammation
H5N1
Human + + + + + +        
Macaque* + + + + + + +  +    +  
Ferret + +  + + + + + + + +  + + +
Cat + +  + + + +  + +     
pH1N1
Human + + + + + + + + + + + + + N N
Macaque + +  + + + + + + +  + + + +
Ferret + +  + + + + + + + + + + + +
Cat + +  + + + +  + +     
Seasonal†
Human + + + + + + + + +  + + + + +
Macaque +   +           
Ferret +   + +  +  + + +  + + +
Cat N N N N N N N N N N N N N N N
Virus and species Virus antigen expression Virus attachment
Type I
pneumocytes
Type II
pneumocytes
Alveolar
macrophages
Bronchiolar
epithelial cells
Bronchial
epithelial cells
Tracheal
epithelial cells
Submucosal
glandular epithelial
cells
Nasal
epithelial cells
Type I
pneumocytes
Type II
pneumocytes
Alveolar
macrophages
Bronchiolar
epithelial
cells
Bronchial
epithelial
cells
Pulmonary
goblet cells
Tracheal
epithelial
cells
Submucosal
glandular epithelial
cells
Nasal
epithelial
cells
H5N1
Human  + +   +    + + + +   + 
Macaque* + + + + +    + +  + +   N N
Ferret + + + + +   +  +      N N
Cat + + + + +     + + +    N N
pH1N1
Human + + + + + + + n + + + + + + + + +
Macaque + +      + N N N N N N N N N
Ferret + + + + + + + + N N N N N N + N +
Cat + + + + +    N N N N N N N N N
Seasonal†
Human     +  + N +   + + + +  +
Macaque                 N
Ferret  +      + +   + +  + + N
Cat                 N
N, not done.
*Cynomolgus macaque.
†Seasonal human influenza virus H1N1 and H3N2.
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90 J.M.A. van den Brand et al.In contrast, animals that have been infected experi-
mentally with SARS-CoV usually do not undergo
intervention and are killed before the endpoint of se-
vere disease. Finally, one should consider that only
about 10% of people with confirmed SARS-CoV
infection die (Peiris et al., 2003b) and it is likely that
many people who recovered from SARS had less se-
vere respiratory tract lesions.The Pathogenesis of Severe Acute Respiratory Syndrome
Coronavirus Infection in Man
The pathological changes induced by SARS-CoV
infection in man can be related to virus-specific fac-
tors and host-specific factors (Tables 3 and 4).
Virus-specific Factors: (1) Receptor Specificity. SARS-
CoV enters the body via the respiratory system by
droplet transmission and interacts with cellular recep-
tors via the surface spike protein (S-protein) to infect
target cells (Simmons et al., 2004). Several host cell re-
ceptors have been found to bind to the S-protein. One
is metallopeptidase angiotensin-converting enzyme 2
(ACE2). Others are lectins: C-type lectin DC-SIGN
(or CD209), human CD209L (or liver/lymph node
specific (L)-SIGN and DC-SIGNR) and LSECtin
(Li et al., 2003; Jeffers et al., 2004; Yang et al., 2004a;
Gramberg et al., 2005). Binding of the S-protein to
the main functional receptor ACE2 on the target
cell leads to fusion between the virus envelope and
the host cell membrane. SARS-CoV infection of
ACE2-expressing cells seems to be dependent on the
lysosomal proteolytic enzyme cathepsin L that is pre-
sent in various cell types (Simmons et al., 2005; HuangTable
Similarities and differences in the path
Similarities
SARS
Pneumocytes main target:
resulting in DAD DAD less fulminant with
regenerative pattern
Hyaline membranes in
human cases Multinucleated cells
Haemophagocytic syndrome
and lymphoid depletion Fibrocellular intra-alveol
with a BOOP-like patter
Hypoxia-related skeletal muscle
and renal tubular necrosis Less rapid, 2nd week of il
Pathology centred around the
bronchioles for SARS and pH1N1 Respiratory tract, intestin
liver, blood, urine and fa
BOOP, bronchiolitis obliterans organizing pneumonia.
Based in part on Ng et al. (2006).et al., 2006b). ACE2 in man is present in type I and II
pneumocytes, small intestinal enterocytes, the brush
border of proximal tubular cells of the kidneys,
endothelial cells of small and large arteries and
veins, and arterial smooth muscle cells (Hamming
et al., 2004). DC-SIGN (or CD209) is expressed on
dendritic cells and macrophages. The low expression
of cathepsin L in human endothelial cells might
explain the low infection rate of these cells despite
their high expression of ACE2 (Huang et al., 2006a).
On the other hand, virus replication was observed
in colonic epithelial cells and in hepatocytes without
ACE2 expression, which may be explained by the
presence of other receptors and co-receptors like den-
dritic cell-specific DC-SIGN and human CD209L
(Lau and Peiris, 2005). Binding of SARS-CoV to
this receptor did not lead to entry of virus into den-
dritic cells, but facilitated transfer of viruses to other
susceptible cells (Yang et al., 2004a). CD209L acted
in conjunction with LSECtin to enhance SARS-
CoV infection (Jeffers et al., 2004).
The main target cells for the virus to infect are
epithelial cells of the respiratory tract, which are
the first cells the virus encounters after entering
the body. The sites of viral replication correspond
with the presence of ACE2. Immunohistochemistry
(IHC) and in-situ hybridization (ISH) studies
demonstrate virus antigen or viral nucleic acid in
alveolar, bronchiolar, bronchial and tracheal
epithelial cells, alveolar macrophages and multinu-
cleated cells (To and Lo, 2004; Shieh et al., 2005).
Co-labelling for cytokeratin and surfactant shows
that the infected cells are mostly pneumocytes,3
ology of SARS and H5N1 influenza
Differences
H5N1 Influenza
Acute alveolar lesions
an acute and DAD more fulminant and necrotizing
with marked haemorrhage
Typical histopathological features
No multinucleated cells
Organizing phase
ar organization
n
Patchy and interstitial paucicellular
fibrosis without BOOP-like pattern
Development of severe disease
lness More rapid, end of 1st week of illness
Dissemination
al tract,
eces
Respiratory tract, intestinal tract, brain,
cerebrospinal fluid and blood
Table 4
Similarities and differences between the pathogenesis of SARS and influenza
Factors important for pathogenesis Similarities Differences
Virus-specific factors
Receptor specificity e Receptors:
SARS: ACE2, DC-SIGN, L-SIGN
Influenza: sialic acids
Direct cytopathic effect e SARS: not so important
Influenza: important
Host-specific factors
Immune cells Lymphopenia
High neutrophil count
e
Imbalanced cytokines e SARS: host specific
Influenza: virus specific
Age Old age is associated with fatal
cases (SARS and seasonal influenza)
Not for pH1N1 and H5N1
Co-morbidity Co-morbidity is associated with fatal
cases (SARS, seasonal influenza and pH1N1)
Not for H5N1
Genetic factors e SARS: certain genetic factors are
associated with severity of disease
Influenza: not described
Species differences Differences in pathological changes and disease
outcome among man and animals are species related
e
Animal Models of SARS and Influenza 91predominantly type II pneumocytes (Shieh et al.,
2005). Type II pneumocytes secrete surfactant,
which is involved in reduction of the surface tension
and integrity of the alveolar lumen, and they are
important in tissue restitution and differentiation
into type I pneumocytes. In extrarespiratory tis-
sues, SARS-CoV RNA is detected in small and
large intestine, lymph nodes, spleen, liver, heart,
kidney, skeletal muscle, adrenal gland and cere-
brum, suggesting that SARS has extra-pulmonary
dissemination leading to virus excretion in respira-
tory secretions, stools, urine and possibly sweat
(Leung et al., 2003; Ding et al., 2004; Farcas et al.,
2005).
Virus-specific Factors: (2) Direct Cytopathic Effect. After
attachment to and infection of the host cells, there
is damage of those cells and surrounding cells with
attraction of inflammatory cells. In the early stage,
the severe oedema, fibrin deposits and haemorrhage,
as is seen in the histopathology of human cases, is
most likely due mainly to the damage to epithelial
cells, with loss of epithelial lining resulting in
vascular leakage. The epithelial damage can partly
be explained by the direct cytopathic effect and
apoptotic mechanisms due to viral infection and
replication, resulting in lysis of the infected cells
and inflammation in the infected tissue (Ng et al.,
2003; Zhou et al., 2006). High titres of virus have
been found in severely damaged organs (Farcas
et al., 2005; Gu et al., 2005), with necrosis at the
sites of virus particles (Nicholls et al., 2003). Fas-mediated apoptosis was demonstrated in human
epithelial cells (Tanaka et al., 2002).
Host-specific Factors: (1) Immune and Inflammatory Cell-
s. Infiltration of stimulated inflammatory cells in-
duces the secretion of additional cytokines and
enhances the inflammation (Yen et al., 2006). Im-
mune and inflammatory cells such as lymphocytes,
monocytes and neutrophils may play a role in the le-
sions caused by SARS-CoV infection. Lymphocytes
such as cytotoxic T cells kill infected cells, monocytes,
macrophages and neutrophils produce proinflamma-
tory cytokines, and neutrophils release granules with
enzymes that cause necrosis in surrounding cells and
attract other inflammatory cells. Lymphopenia with
a rapid decrease of CD4+ and CD8+ T cells and a
high neutrophil count was seen in the blood of hu-
man patients in the acute phase of SARS-CoV infec-
tion, and was associated with an adverse outcome
(Wong et al., 2003).
Host-specific Factors: (2) Induction of Cytokines. Next to
damage due to virus replication, the severe pulmo-
nary damage may be attributed to an excessive host
immune response with the production of proinflam-
matory cytokines, as is demonstrated in cytokine
and chemokine profiles (Nicholls et al., 2003; Peiris
et al., 2003a; Wong et al., 2004; Zhang et al., 2004).
In SARS patients, the results of cytokine and
chemokine measurements are difficult to interpret
due to many confounding factors. However, the
levels of both cytokines and chemokines in the blood
92 J.M.A. van den Brand et al.are elevated: interleukin (IL)-1, IL-6, IL-8, IL-12,
IFN-g, monocyte chemotactic protein (MCP)-1 (or
CC-motif ligand 2, CCL2), monokine induced by
IFN-g (MIG), IFN-inducible protein (IP-10 or che-
mokine C-X-C motif ligand 10, CXCL10) and trans-
forming growth factor (TGF)-b (Wong et al., 2004;
Zhang et al., 2004; Huang et al., 2005; Jiang et al.,
2005; Tang et al., 2005; Baas et al., 2008). Increased
expression of chemokines and cytokines such as IP-
10, MCP-1, IL-6 and IL-8 are important for chemo-
taxis and activation of neutrophils and monocytes
(Ware and Matthay, 2000; Fan et al., 2001;
Tsushima et al., 2009). Infiltration of these
inflammatory cells corresponds with the severe
pulmonary lesions observed in human cases (Huang
et al., 2005; Jiang et al., 2005; Cameron et al., 2007;
Smits et al., 2010).
The production of type I IFNs by the host after
infection with a virus is an essential part of the anti-
viral innate immune system. SARS-CoV is suggested
to cause inhibition of IFN production (Weber et al.,
2004). In people with SARS, treatment with type I
IFNs was associated with reduced disease-associated
hypoxia and a more rapid resolution of radiographic
lung abnormalities (Loutfy et al., 2003).Host-specific Factors: (3) Risk Factors
Themost important host-specific risk factors in people
for more severe SARS-related disease and deaths due
to acute respiratory distress syndrome (ARDS) are
advanced age, sex and co-morbidities (Chan-Yeung
and Xu, 2003; Donnelly et al., 2003; Lee et al., 2003;
Manocha et al., 2003; Karlberg et al., 2004; Leung
et al., 2004; Liu et al., 2006; Lau et al., 2010).
Additionally, genetic factors such as certain human
leucocyte antigen (HLA) haplotypes are associated
with a higher susceptibility to SARS-CoV infection
in man (Ng et al., 2004; Ip et al., 2005). In contrast,
L-SIGN homozygote individuals have a lower
susceptibility to SARS-CoV infection (Chan et al.,
2006). Additionally, there may be another genetic
factor involved in the protection against human
SARS-CoV infection; genotypes producing low con-
centrations of mannose-binding lectin, a collectin in
the serum that is able to bind the glycosylated S-pro-
tein, were associated with increased risk of developing
SARS (Ip et al., 2005).The Pathogenesis of Severe Acute Respiratory Syndrome
Coronavirus Infection in Animal Models
Variation in disease severity in animal models can be
explained by both virus-specific and host-specific fac-
tors.Virus-specific Factors. In laboratory animals, cell type
tropism of SARS-CoV is related to ACE2 expression
(Table 1, Fig. 2). Similar to humanACE2, both ferret
and feline ACE2 bind the attaching S-protein of
SARS-CoV efficiently (Zamoto et al., 2006; Guo
et al., 2008). However, cell tropism and ACE2
expression do not always correspond. For example,
ferret bronchiolar epithelial cells express ACE2, but
are apparently not infected by SARS-CoV (Table
1). This discrepancy may be explained by the neces-
sity for other receptors besides ACE2 for virus attach-
ment or for other factors (such as cathepsin L) for
SARS-CoV replication in the host cell (Gramberg
et al., 2005).
Another discrepancy between cell type tropism and
ACE2 expression was observed in tracheobronchial
submucosal glands. While the submucosal glands of
both cats and ferrets expressed ACE2, only the sub-
mucosal glands of cats became infected and inflamed.
As indicated above, this discrepancy may be due to
species differences in expression of other co-factors
necessary for viral replication. Alternatively, this
discrepancy may also be due to species differences in
the histological architecture of the tracheobronchial
submucosal glands, which contain both serous and
mucous cells. Ferrets have relatively more mucous
cells than cats. This may have inhibited the attach-
ment of SARS-CoV to serous cells, which was the
main cell type infected in cats.
Most likely, direct cytopathic damage due to virus
replication in SARS is not the most important factor
for cellular and tissue damage in animal models, since
differences in the severity of the pulmonary lesions be-
tween young-adult and aged macaques were
observed, despite having similar virus loads.
Several genetic factors of both the virus and the host
are known to modify the susceptibility and immune
response to SARS-CoV infection. Genetic analyses
of SARS-CoV demonstrate that genetic variation in
the spike gene of SARS-CoV isolates from civet cats
causes increased transmission and affinity of the virus
for both civet and humanACE2 receptors (Tang et al.,
2006; Rockx et al., 2009).
Host-specific Factors. SARS-CoV-infected young-adult
and agedmacaques demonstrated expression of various
cytokines and chemokines such as IP-10, MCP-1, IL-6
and IL-8 in the lungs in a similar pattern as was seen in
man (de Lang et al., 2007). The cytokine response in
SARS is probably host specific since aged macaques
had a stronger up-regulation of those chemokines and
cytokines than young-adult macaques, despite similar
virus replication (Smits et al., 2010). When up-regu-
lated chemokines and cytokines of macaques and
AGMs were compared, IP-10, MCP-1, CXCL-1,
Fig. 2. Cell type tropism in the respiratory tract of cats and ferrets infected experimentallywithH5N1 influenza virus andSARS-CoV.The
presence of receptors is demonstrated for SARS-CoV by the expression of ACE2 by IHC and for H5N1 by the expression of virus
attachment by virus histochemistry. The presence of virus in similar cell types is demonstrated by virus antigen expression by IHC.
Bars, 10 mm.
Animal Models of SARS and Influenza 93CXCL2, IL-6 and IL-8 were up-regulated in ma-
caques, but not in AGMs. However, despite similar vi-
rus replication levels, the young-adult AGMs showed
more severe lesions with hyaline membranes when
compared with the young-adult macaques. Compara-
tive gene expression analyses revealed induction of
proinflammatory and antiviral pathways in both spe-
cies. Cytokines important for ARDS or neutrophils at-
tracting activity, such as CXCL-1, CXCL2, IL-6 andIL-8, were up-regulated in the macaques, but not in
the AGMs. Other proinflammatory chemokines and
cytokines such as SPP1 (osteopontin), CCL20 and
CCL3 were up-regulated more in AGMs than in ma-
caques. Additionally, osteopontin and CCL20 were
significantly more up-regulated in AGMs and aged
macaques than in young-adult macaques. Osteopontin
is expressed predominantly by macrophages and is
important in type 1 (Th1) cytokine expression and
94 J.M.A. van den Brand et al.plays a role in development of lung fibrosis (O’Regan,
2003; Pardo et al., 2005). In AGMs, many
macrophages, presumed to express osteopontin, were
seen histologically, while in macaques there were both
macrophages and neutrophils. The above-mentioned
differences in the gene expression profile as well as the
difference in the tropism, which also involves bronchi-
olar and tracheal epithelial cells in AGMs (Table 1),
help to explain the more severe lesions in the AGMs.
When macaques experimentally infected with
SARS-CoV were directly treated with IFN, there
was also a protective effect, suggesting that
supplementing IFN as a therapy can be beneficial
(Haagmans et al., 2004). These results demonstrate
that the inhibition of IFN production caused by the
virus plays an important role in the induction of virus
replication and associated severe lesions after SARS-
CoV infection.
Genetic analyses of the host demonstrate that
species-to-species variation in the sequence of the
ACE2 gene affects the efficiency by which the virus
can enter the cells (Li et al., 2005c). The differences
in disease outcome between the species can be attrib-
uted to the differences in cell type tropism of SARS-
CoV (Table 1) and the differences between cynomol-
gus macaques and AGMs in induction of cytokines
(Smits et al., 2010). The cell type tropism as described
in virus-specific factors by the distribution of ACE2
may result in differences in the severity of the disease
between animal models and man. Additionally, the
difference in the outcome of the disease between
AGMs and cynomolgus macaques indicates that
there may be more differences in the reaction of the
immune response between the species. These differ-
ences may be related to evolutionary adaptations
and differences in selection of major histocompatibil-
ity complexes, immune response, cytokine production
and sensitivity to viruses. Co-morbidities and genetic
factors that are associated with severe disease in man
have not been investigated in laboratory animals and
thus an insight into those factors from SARS animal
models has not been obtained.
Age is another host-specific factor that is related to
more severe disease in man. Aged cynomolgus ma-
caques (10e19 years old) infected with SARS-CoV
had more severe lesions than young-adult animals
(3e5 years old), even though viral replication levels
were similar (Imai et al., 2008; Smits et al., 2010;
Rockx et al., 2011). Additionally, aged mice showed
more severe lesions than young-adult mice on
infection with SARS-CoV and the transcription pro-
file in aged mice generally indicated a stronger proin-
flammatory response than in young mice (Baas et al.,
2008; Rockx et al., 2009). It is suggested that age-
related accumulated oxidative damage and a weak-ened anti-oxidative defence system cause a distur-
bance in the redox balance, resulting in increased
reacting oxygen species (Smits et al., 2010). Subse-
quently, redox-sensitive transcription factors, such
as nuclear factor (NF)-kB, can be activated, which
is followed by the induction of proinflammatory genes
such as IL-1b, IL-6, TNF-a and adhesion molecules
(Chung et al., 2006). Therefore, ageing is not only
associated with alterations in the adaptive immune
response, but also with a proinflammatory state in
the host (Smits et al., 2010). Oxidative stress and
Toll-like signalling, via NF-kB triggered by viral
pathogens like SARS-CoV, may further amplify the
host response, ultimately leading to acute lung injury
(Imai et al., 2008).Influenza A Virus
Background
Influenza was first described as epidemics of acute,
rapidly spreading catarrhal fevers in man and the first
epidemic was most probably described by Hippocrates
in 412 B.C. (Beveridge, 1978; Cox and Subbarao,
2000). Epidemics or pandemics of influenza have
occurred throughout the last 2,500 years of history.
Today, human influenza occurs yearly as seasonal
influenza, mainly in the winter months of temperate
climates, every year as interpandemic epidemics, and,
sporadically at an average of 35 year intervals, as
more severe influenza (i.e. pandemics). Seasonal
influenza and interpandemic epidemics occur as a
result of mutations in influenza viruses that are
circulating in the human population (antigenic drift).
In contrast, influenza pandemics occur as a result of
the introduction of an animal influenza virus or a
humaneanimal influenza reassortant virus in which
the surface glycoprotein haemagglutinin, with or
without other virus proteins, substantially differs
antigenically from those circulating in the human
population (antigenic shift) (CoxandSubbarao, 2000).
Since 1900, there have been four pandemics of hu-
man influenza: 1918 H1N1 ‘Spanish’ influenza, 1957
H2N2 ‘Asian’ influenza, 1968 H3N2 ‘Hong Kong’
influenza and the 2009 H1N1 ‘Swine’ influenza (Cox
and Subbarao, 2000; Morens et al., 2009). Of these,
the 1918 ‘Spanish’ influenza pandemic was the worst,
causing acute illness in 25e30% of the world
population and the death of nearly 50 million people
(Parker and Caywood, 1987; Jepson et al., 1997;
Osterhaus, 2001). Most of the fatalities occurred
among 15e34 year olds, with primary acute interstitial
pneumonia, pulmonary haemorrhage and pulmonary
oedema, often with secondary bacterial pneumonia
(Parker and Caywood, 1987; Osterhaus, 2001).
Animal Models of SARS and Influenza 95Influenza A virus infections occur in both mammals
and birds and are classified, based on surface glycopro-
teins, into 17 haemagglutinin (HA) (H1eH17) and
nine neuraminidase (NA) (N1eN9) subtypes
(Swayne and Halvorson, 2003; Tong et al., 2012).
Avian influenza virus can be of high or low
pathogenicity (HPAI or LPAI) based on the
pathogenicity for chickens. During human infection,
human influenza viruses use host trypsin-like proteases
in the respiratory tract to cleave HA, while LPAI vi-
ruses replicate in both the respiratory and the digestive
tracts of birds (WHO, 2004). HPAI viruses use a wide
range of proteases allowing replication outside the res-
piratory tract in chickens (Horimoto and Kawaoka,
2001).
The HPAI virus H5N1 was initially present in
poultry, but in 1997 it crossed the species barrier
and infected men in China (Claas et al., 1998).
H5N1 continues to circulate among poultry in
many countries in Asia, Africa and Europe, and occa-
sionally spreads to people, often with fatal conse-
quences. H5N1 is the first avian influenza virus to
cause significant numbers of human infections and
deaths (i.e. 604 infections with 357 fatalities since
January 2004) (Swayne and Halvorson, 2003;
WHO, 2012).
At the start of April 2009, a novel H1N1 influenza
A virus (pH1N1) was identified as the cause of acute
respiratory disease of people in Mexico (Garten et al.,
2009). This virus was a complex reassortant influenza
A virus, which had not been previously reported in
animals, but had gene segments related to North
American classic H1N1 swine viruses (haemaggluti-
nin, nucleoprotein and non-structural gene seg-
ments), North American avian viruses (polymerase
A and B2 genes), human influenza A virus (polymer-
ase B1 genes) and Eurasian H1N1 swine viruses
(neuraminidase and matrix genes) (Garten et al.,
2009). On 1 August 2010, at the end of the pandemic,
more than 214 countries had reported laboratory
confirmed cases of this pH1N1, including at least
18,449 deaths (WHO, 2010).The Pathology of Influenza in Man
Uncomplicated influenza is a mild inflammation of the
upper respiratory tract that consists mainly of rhinitis,
paranasal sinusitis, pharyngitis and laryngitis. Histo-
pathologydemonstrates diffuse, superficial, necrotizing
tracheobronchitis characterized by desquamation of
epithelial cells, oedema and hyperaemia in the lamina
propria and infiltration with lymphocytes and histio-
cytes. The inflammation is short lasting: epithelial
regeneration is already visible within 2 days after onset
of symptoms (Walsh et al., 1961).Viral pneumonia is a complication of influenza vi-
rus infection. Gross examination of the lungs shows
extensive consolidation with varying degrees of hae-
morrhage. Histopathology caused by influenza virus
infection of the alveoli consists of DAD, which has
the same general pathological features as in SARS,
except that syncytia are not observed and in the
fibrotic phase there is no bronchiolitis obliterans orga-
nizing pneumonia-like appearance (Ng et al., 2006;
Taubenberger and Morens, 2008). Influenza viral
pneumonia often occurs together with, or is followed
by, bacterial pneumonia.
The pathology of pH1N1 infection in fatal human
cases when comparedwith human cases ofH5N1 infec-
tion showed similar DAD. However, fatal cases of
pH1N1 infection showed more inflammation in the
nose, trachea, bronchi and bronchioles, a feature that
was also seen in fatal cases of seasonal influenza
(Guarner et al., 2006; Guarner and Falcon-Escobedo,
2009). H5N1 virus infection has also been associated
with extrarespiratory disease. In the lymphoreticular
system there was marked histiocytic hyperplasia and
reactive haemophagocytic syndrome. Other lesions
included atrophy of white pulp in the spleen,
centrilobular necrosis in the liver, acute tubular
necrosis in the kidney, necrosis of skeletal muscle
fibres and necrosis in the brain with microglial
nodules (To et al., 2001; Peiris et al., 2004b;
Chokephaibulkit et al., 2005; Uiprasertkul et al.,
2005). Infection with pH1N1 rarely demonstrates
haemophagocytosis or neuromuscular and cardiac
complications (Rothberg et al., 2008). Infection with
seasonal influenza virus primarily infects and causes
disease in the respiratory tract and is associated, albeit
to a lesser extent, with disease in extrarespiratory or-
gans. These include influenza-associated acute enceph-
alopathy (Studahl, 2003), myocarditis (Ray et al.,
1989) and myopathy (Agyeman et al., 2004).Animal Models for Human Influenza
Animal models help both to better understand influ-
enza in man and to develop medical countermeasures
against this disease. Forms of influenza inman forwhich
animal models have been developed include uncompli-
cated influenza, influenza pneumonia, influenza-
associated bacterial sepsis, influenza-associated neuro-
logical disease, influenza in immunocompromised
hosts and virus transmission (Barnard, 2009). Specific
goals forwhich animalmodels are designed are to deter-
mine transmissibility of different viruses, virulence of
different viruses, pathogenesis of viral infection and effi-
cacy of vaccines or antiviral drugs.
Experimental animal species used include the labo-
ratory mouse, domestic ferret (Beigel et al., 2005),
Fig. 3. Virus antigen expression (IHC) and histopathology (HE) of respiratory tissue in ferrets infected with different influenza viruses;
seasonal H3N2 (AeD), pH1N1 (EeH) and H5N1 (IeL). Bars, 50 mm (bronchiole). Bars, 25 mm (alveoli).
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Animal Models of SARS and Influenza 97Syrian hamster (Friedewald and Hook, 1948), chin-
chilla (Giebink et al., 1980), domestic horse
(Wattrang et al., 2003), laboratory rat (Rubin et al.,
2004), domestic dog (Giese et al., 2008), domestic
cat (Rimmelzwaan et al., 2006), cotton rat
(Boukhvalova et al., 2009), domestic pig (Lipatov
et al., 2008), guinea pig (Kwon et al., 2009) and
non-human primates (e.g. squirrel monkeys, cyno-
molgus macaque and rhesus macaque) (Murphy
et al., 1982; Kuiken et al., 2003b; Chen et al., 2009).
Cynomolgus macaques have been used in
pathogenesis studies and vaccination studies
(Kreijtz et al., 2009). Ferrets have been used to model
uncomplicated upper respiratory tract infection, to
model viral pneumonia and to model influenza virus
transmission among people (Munster et al., 2009;
van den Brand et al., 2010a). Cats have been used to
model systemic disease after infection with H5N1
influenza and to investigate the pathogenesis of
H5N1 (Rimmelzwaan et al., 2006). The lesions of ma-
caques, ferrets and cats infected withH5N1match the
clinical signs, virus replication and associated lesions
in the respiratory tract, followed by death as is seen
in man. However, there are differences between ani-
mal species and people infected with influenza virus.
Therefore, the animal model used for severe disease
in man needs proper consideration of all aspects of
the model including animal species, inoculation route
and inoculum dose. This review focuses on the patho-
logical changes related to the pathogenesis of different
influenza virus infections in macaques, ferrets and
cats.
Non-Human Primates. The cynomolgus macaque is a
non-human primate that is often used as an animal
model for human disease caused by influenza
virus infection (Kuiken et al., 2003b; Herfst et al.,
2010). Experimental H5N1 infection in cynomolgus
macaques causes both morbidity and mortality
(Kuiken et al., 2010). Microscopical lesions are centred
in the alveoli and bronchioles and consist of DAD that
is more severe than for human influenza viruses (Table
2, Fig. 1) (Rimmelzwaan et al., 2001; Kuiken et al.,
2003b; Kreijtz et al., 2009). Extrarespiratory tissues
do not show histological lesions (Rimmelzwaan et al.,
2001; Kuiken et al., 2003b; Baskin et al., 2009; Chen
et al., 2009), although suppurative tonsillitis,
lymphocytic necrosis in lymphoid organs, hepatic
necrosis and renal tubular necrosis are seen rarely
(Rimmelzwaan et al., 2001; Kuiken et al., 2003b).
Experimental pH1N1 infection in cynomolgus
macaques causes morbidity, but no mortality.
Microscopical lesions consist of multifocal moderate
DAD (Table 2). In addition, there is moderate bron-
chiolitis and mild bronchitis, tracheitis and rhinitis.The severity of pH1N1-induced pulmonary lesions is
higher than those induced by seasonal influenza
H1N1, but lower than those induced byH5N1. Exper-
imental seasonal influenza virus infection in cynomol-
gus macaques also causes morbidity, but no
mortality. Microscopical lesions consist of focal to
multifocal mild DAD with mild necrosis and no
oedema, hyaline membranes or lesions in the other
parts of the respiratory tract (Herfst et al., 2010).
Carnivores. A more frequently used animal species in
influenza research is the ferret. Intratracheal inocula-
tionof influenzavirus into ferrets causes highmorbidity
andmortality for H5N1 (Rowe et al., 2003; Govorkova
et al., 2005; Cameron et al., 2008), moderate morbidity
and low mortality for pH1N1 (van den Brand et al.,
2010a) and neither obvious morbidity nor mortality
for seasonal influenza virus (Zitzow et al., 2002). This
corresponds to differences in severity of pulmonary le-
sions (consisting of DAD), which is high for H5N1
(Fig. 1), intermediate for pH1N1 and low for seasonal
H1N1. The extent and distribution of the lesions
throughout the respiratory tract also differ between
the viruses (Table 2). Extrarespiratory lesions are
limited to H5N1 infection and consist of non-
suppurative necrotizing encephalitis (Boltz et al.,
2008), multifocal hepatitis, necrosis and hyperplasia
of bile duct epithelium (Govorkova et al., 2005; Yen
et al., 2007; Boltz et al., 2008; Kuiken et al., 2010).
When pH1N1 is inoculated intranasally into ferrets
instead of intratracheally, lesions occur higher in the
respiratory tract and consist of a mild to moderate
necrotizing bronchiolitis, bronchitis, tracheitis and
rhinitis (Munster et al., 2009). Intranasal inoculation
of H5N1 in ferrets results primarily in encephalitis,
compared with pneumonia after intratracheal inocu-
lation (Bodewes et al., 2011; Schrauwen et al., 2012).
This illustrates the effect of route of inoculation on
the pathogenesis of experimental influenza virus
infection (Bodewes et al., 2011).
The temporal and spatial dynamics after combined
intranasal and intratracheal inoculation of influenza
virus in ferrets differ between viruses (van den Brand
et al., 2012a) (Fig. 3). H5N1 infection causes predom-
inantly moderate DAD and bronchiolitis, starting at
12 h post infection (hpi), developing into severe
DAD with oedema from 1 to 4 days post infection
(dpi) and necrosis and inflammation in the bronchus,
trachea and nose. pH1N1 infection causes mild lesions
at 12 hpi, developing into moderate to severe lesions
from 1 to 7 dpi, with more involvement of the nose
when compared with ferrets infected with H5N1. At
14 dpi the lesions are again mild (van den Brand
et al., 2012a). Human seasonal influenza virus infection
does not consistently cause viral pneumonia, but is
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and rhinitis (Svitek et al., 2008; Munster et al., 2009).
Several felid species are susceptible to severe or fatal
disease from influenza virus infection, as suggested by
natural cases of H5N1 and/or pH1N1 infection in
cats, tigers and leopards (Keawcharoen et al., 2004;
Lohr et al., 2010; Sponseller et al., 2010; van den
Brand et al., 2010b). Intratracheal inoculation of
influenza virus into cats causes morbidity and
mortality for H5N1 (Rimmelzwaan et al., 2006),
morbidity, but no mortality for pH1N1 and lack of
infection for seasonal H3N2 (Rimmelzwaan et al.,
2006; van den Brand et al., 2010b). This corresponds
to more severe DAD for H5N1 than for pH1N1, as
seen in ferrets (Table 2). Extrarespiratory lesions,
characterized by inflammation and necrosis in the
brain, heart, kidney, liver and adrenal gland, are
limited to H5N1 infection (Rimmelzwaan et al.,
2006), and are much more extensive than in ferrets.Comparative Pathology
The pathological changes of influenza virus infec-
tion in fatal human cases and in laboratory animals
show both differences and similarities (Table 2).
These can be compared according to localization,
character, severity and temporal changes in the le-
sions, and the degree of extrarespiratory spread.
Firstly, the localization of the lesions in the respira-
tory tract, between different viruses, in general is
similar for man and laboratory animals. In seasonal
influenza infection, the upper respiratory tract is
mostly affected, in pH1N1 infection, all parts of
the respiratory tract are affected, and in H5N1
infection, the lower respiratory tract is mostly
affected (Guarner et al., 2006; Shieh et al., 2010;
van den Brand et al., 2012a). There are some
differences in localization, since H5N1 infection in
laboratory animals involves more of the air-
conducting parts of the respiratory tract than in
man, and vice versa for pH1N1 and seasonal influ-
enza virus infections. Secondly, the character of the
respiratory tract lesions is similar for man and lab-
oratory animals. This includes the alveolar lesions
after infection with H5N1 and pH1N1. These alve-
olar lesions result in DAD characterized by necrosis
of epithelial cells, oedema, infiltration of inflamma-
tory cells and epithelial regeneration. Thirdly, the
severity of the respiratory tract lesions appears
greater in man than in laboratory animals. For
example, fatal human cases often show alveolar
oedema and hyaline membranes, which are less
common in laboratory animals. One factor may
be that laboratory animals are killed before severe
disease or death occurs. Fourthly, the temporal dy-namics of influenza virus infection in ferrets may
reflect the differences in the age of pathological
changes in fatal human cases due to the duration
of their illness before dying. Fifthly, the degree of
extrarespiratory involvement of H5N1 infection in
man is difficult to compare with that in laboratory
animals because it is so poorly described in man.
The involvement of the CNS in some human cases
of H5N1 infection (de Jong et al., 2005) appears
similar to that in ferrets, where extrarespiratory
spread often is limited to the CNS. In contrast, ex-
trarespiratory spread of H5N1 in man is probably
not as common or as widespread as in cats
(Rimmelzwaan et al., 2006). Overall, many features
of the pathological changes in man and laboratory
animals are similar. The choice of animal model,
including laboratory animal species, route of virus
inoculation and dose of inoculum, will depend on
the specific feature of influenza in man that one
wishes to study.The Pathogenesis of Influenza Virus Infection in Man
As in SARS, the pathology of influenza in fatal human
cases can be related to factors that have been proven
important in influenza virus infection: virus-specific
factors and host-specific factors (Tables 3 and 4).
Virus-specific Factors: (1) Receptor Specificity. As in
SARS-CoV infection, the route of entry is airborne
transmission into the respiratory system. Attachment
of the viral haemagglutinin to its host cell receptor is
the first step in the influenza virus replication cycle.
The receptor on the surface of the host cell is a sialic
acid (SA)-terminated glycan. Human-adapted influ-
enza viruses prefer binding of an a-2,6 SA linkage,
which is present throughout the human respiratory
tract, while avian influenza viruses prefer binding by
an a-2,3 SA linkage, which is abundantly present in
the respiratory and intestinal tract of aquatic birds
(Connor et al., 1994; Shinya et al., 2006). Because
different influenza viruses use different SAs as their
receptor, and because the expression of SAs differs
both across the respiratory tract and across species,
this step influences both the pattern of disease in the
respiratory tract and the host range of virus infection.
In people, human-type receptors are predomi-
nantly expressed on the epithelium of the upper
part of the respiratory tract (i.e. nose, trachea and
bronchi), while avian-type receptors are mainly ex-
pressed in the epithelium of the lower part of the res-
piratory tract (i.e. bronchi, bronchioles and type II
pneumocytes) (Shinya et al., 2006; Nicholls et al.,
2007). Where virus attachment studies show the
cells to which influenza viruses bind, virus antigen
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influenza viruses actually replicate.
Virus-specific Factors: (2) Direct Cytopathic Effect. The
severe damage to type I and type II pneumocytes
allows fluid to flood into and accumulate in the
alveolar lumina. This has severe consequences for
the gas exchange function of the respiratory tract,
resulting in severe and, in some cases, fatal respira-
tory dysfunction as is also seen in SARS-CoV infec-
tion (Ware and Matthay, 2000). Damage to the
alveolar epithelium is in part due to the direct cyto-
lytic effect of virus infection. The cytolytic effect
could be due to necrosis or apoptosis as a result of
replication of the virus. Direct cytopathic damage
is suggested by high virus titres found in severely
damaged lung tissue as well as in throat or nose
swabs (Hien et al., 2004; Peiris et al., 2004b), while
virus antigen expression in epithelial cells was
associated with severe DAD (Uiprasertkul et al.,
2005, 2007; Kuiken et al., 2010).
Host-specific Factors: (1) Immune and Inflammatory Cells. As
in SARS, immune cells such as lymphocytes, mono-
cytes and neutrophils play a role in the lesions caused
by influenza virus infection. In fatal human cases of
H5N1 and pH1N1 infections, lymphopenia was asso-
ciated with severe disease (Yuen et al., 1998; Perez-
Padilla et al., 2009).
Host-specific Factors: (2) Cytokines. As in SARS, fatal
infection with H5N1 is associated with elevated con-
centrations of serum cytokines (de Jong et al., 2006;
Uiprasertkul et al., 2007). Chemokines and
cytokines such as IP-10, MIG, MCP-1, IL-8, IL-10,
IL-6, IL-1a and -b, and IFN-g are elevated in the
serum of patients infected with H5N1 and are partic-
ularly high in fatal cases. The cytokine levels correlate
with the pharyngeal viral load, suggesting that the
increased levels may reflect the viral replication (de
Jong et al., 2006). Cytokine levels are not only
elevated in the serum, but high expression of TNF-a
also is detected in the lungs of fatal cases of H5N1
infection (Peiris et al., 2004b). The high viral load
accompanied by high cytokine response may suggest
a balanced response.
Host-specific Factors: (3) Risk Factors. Important host-
specific risk factors for severe disease from human sea-
sonal influenza virus infection are advanced age, co-
morbidities such as pulmonary disease and cardiovas-
cular disease, and pregnancy (Morens and Fauci,
2007; Taubenberger and Morens, 2008). Risk factors
for severe disease from pH1N1 infection are in general
similar to those for human seasonal influenza virus. Inaddition, they include diabetes, hypertension and
obesity. Interestingly, advanced age does not appear
to be a risk factor for severe disease from pH1N1 or
H5N1 infections. Most patients with pH1N1 infection
were (young) adults, with a median age of 36 years
(Shieh et al., 2010), while most severe human cases of
H5N1 infectionwere previously healthy, with amedian
age of 18 years (WHO, 2012). In addition, the differ-
ence in disease between species is another important
host-specific factor.
Advanced age as a risk factor for severe disease from
seasonal influenza virus infection may be related to
increased host responses and decreased defence mech-
anisms against redox-induced damage, as is seen in
SARS-CoV infection. The different age distribution
of disease and fatality from H5N1 infection may
reflect age-related patterns of exposure or risk behav-
iour such as close contact with sick poultry or age-
related host resistance (Peiris et al., 2007). The
different age distribution of fatality from pH1N1
infection is probably related to the presence of immu-
nity from previous infections with H1N1 influenza vi-
ruses in older people. Because these viruses were
antigenically related to pH1N1, the antibodies were
cross-reactive and therefore protected from severe dis-
ease from pH1N1 infection (Hancock et al., 2009).
Other host-specific factors such as pre-existing mor-
bidities and pregnancies, which are risk factors for sea-
sonal and pH1N1 infection, may be related to a
compromised immune system in chronically ill patients
and pregnant women as well as aerodynamic ventila-
tion problems in advanced pregnancy and obesity.The Pathogenesis of Influenza Virus Infection in Animal
Models
Virus-specific Factors. The receptor distribution differs
between man and different animal species, as is deter-
mined by virus attachment studies (Table 2, Fig. 2)
(van Riel et al., 2006). Those studies reveal that for
H5N1 the virus attachment pattern in respiratory tis-
sues of cats best resembles that of man. For seasonal
influenza virus, the virus attachment pattern in respi-
ratory tissues of ferrets best resembles that of man. For
pH1N1, there are few data about virus attachment in
animals.
Both the pattern of virus attachment and pattern of
virus antigen expression are linked to the severity of
disease and pattern of lesions in the respiratory tract
in man and animals infected with influenza viruses
(Table 2). Overall, the pattern of virus attachment
and pattern of virus antigen expression corresponds
with each other, but not always. A first reason for
this discrepancy may be that, like SARS-CoV, influ-
enza viruses also require other co-receptors or other
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reason may be the influence of surfactant proteins
that protect against influenza in man and pigs and
possibly in other animal species, explaining virus
attachment without virus antigen expression (Benne
et al., 1995).
To choose the most appropriate laboratory animal
species for animal models of influenza inman, it is use-
ful to compare the pattern of virus antigen expression
among species (Fig. 1). ForH5N1, the pattern of virus
antigen expression shows more pulmonary epithelial
cell types showing virus antigen expression in labora-
tory animals than in man. For pH1N1, the pattern of
virus antigen expression in ferrets most closely resem-
bles that in man. For seasonal influenza viruses, the
pattern of virus antigen expression differs between
man, cynomolgus macaques and ferrets. When
comparing the results of virus antigen expression
studies in experimentally infected animals and fatal
human cases, the following factors need to be taken
into account: route of virus entry, dose of virus inoc-
ulum, stage of disease at which tissue samples are
taken, and immune status. The route of entry in ani-
mal models is mostly by intranasal or intratracheal
inoculation, while in man it is by air through small
or large droplets. The dose of the virus inoculum in
animal experiments is usually much higher than in
human infection. Tissue samples are often taken at
an earlier, less severe stage of disease in laboratory an-
imals than in man. Tissue sampling in laboratory an-
imals is usually from non-fatal cases, because the
animals are killed before they succumb to the infec-
tion. In contrast, tissue sampling in people is usually
from fatal cases, where patients have died after pro-
tracted disease and multiple therapeutic interven-
tions. Finally, the immune status is different:
laboratory animals are usually na€ıve to influenza vi-
rus, whilemany people have specific immunity, which
may alter the course of subsequent influenza virus in-
fections.
In animal models, high virus titres in the lungs
strongly suggest active viral replication in those tissues
with subsequently more damage (Zitzow et al., 2002;
Govorkova et al., 2005; Maines et al., 2005;
Rimmelzwaan et al., 2006). Apoptotic damage is
suggested by experiments with TNF-related
apoptosis-inducing ligand (TRAIL)-expressing mac-
rophages that induced epithelial cell apoptosis in
influenza virus pneumonia (Takizawa et al., 1993;
Lowy, 2003; Herold et al., 2008). Additionally,
apoptosis may be induced by up-regulation of certain
chemokines and cytokines (Uiprasertkul et al., 2007).
These findings suggest that direct damage of the virus
by cytopathic and apoptotic mechanisms is important
in the development of pathological changes in influ-enza virus infections. However, damage due to other
mechanisms, such as indirect damage of the host
response, cannot be excluded.
The differences in genetic factors of the different
influenza viruses have a substantial impact on the
outcome of disease after infection. Influenza viruses
change over time due to antigenic shift and drift.
Avian influenza viruses are known to infect people
and pigs and are endemic among poultry without
overt disease. When such avian viruses combine
gene segments and surface proteins from human or
porcine influenza viruses due to reassortment, the re-
assortants may have altered receptor binding proper-
ties, leading to enhanced ability to infect and spread
among people. The presence of cross-reactive anti-
bodies against other subtypes may explain the rela-
tively low mortality in older pH1N1 patients due to
cross-reactive antibodies acquired during previous
influenza infection. The differences in disease after
infection with various subtypes indicate the impor-
tance of virus-specific genetic factors in the course of
the disease.
Host-specific Factors. After H5N1 inoculation, the
number of monocytes in the blood and alveoli of fer-
rets decreased and remained low, suggestive of
exhaustion of the bone marrow (Tumpey et al.,
2000). After pH1N1 inoculation there was an increase
in blood monocytes a few days later (van den Brand
et al., 2012a). Additionally, the neutrophil count in
the blood of ferrets was lower with H5N1 infection
than with pH1N1 infection, as was also seen in human
cases (Hien et al., 2009). This decreased neutrophil
count may be attributed to a higher demand of neu-
trophils than can be met by myelopoiesis. This is
corroborated by the high number of immature neu-
trophils in the blood, again suggesting exhaustion of
the myelopoietic component.
Host genetic factors that influence the outcome of
the disease are not known for man or animals. Differ-
ences in histopathological changes, antigen expres-
sion and receptor specificity between people and
laboratory animal species are species related, as was
seen in SARS-CoV infection. Macaques infected
with H5N1 displayed severe disease and activation
of proinflammatory cytokine and chemokine re-
sponses (Baskin et al., 2009). In ferrets, H5N1 infec-
tion also induced severe disease associated with
strong expression of interferon response genes,
including the IFN-g-induced chemokine CXCL10.
When those ferrets were treated with an antagonist
of the CXCL10 receptor (CXCR3), the severity of
H5N1-related disease and the viral titres were
reduced when compared with controls (Cameron
et al., 2008). For pH1N1, the abundance of
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corresponded with up-regulation of CCL2, CCL3,
CCL8, CXC10, IL-8 and CXCL1, which are known
chemoattractants for neutrophils andmonocytes, as is
seen in macaques. Compared with lungs of cynomol-
gus macaques infected with seasonal humanH1N1 vi-
rus, concentrations of MCP-1, MIP-1a, IL-6 and IL-
18 were higher. This is in line with the more severe
pulmonary lesions in cynomolgus macaques infected
with pH1N1 than with seasonal human influenza
H1N1 virus (Itoh et al., 2009). On the contrary, alve-
olar macrophages infected with H5N1 did not induce
excessive TNF-a. However, alveolar macrophages
were infected more abundantly by H5N1 than by sea-
sonal H1N1 or pH1N1 (van Riel et al., 2011). There-
fore, the imbalance in the level of virus infection and
resultant cytokine and chemokine production may at
least in part contribute to the development of lesions
after infection with H5N1 and pH1N1.Comparing the Pathology and Pathogenesis
of Severe Acute Respiratory Infection
Syndrome and Influenza
When comparing SARS and influenza, there are both
similarities and differences in pathology and patho-
genesis (Table 3). In both diseases the respiratory
tract is the main tissue affected and the changes are
characterized by DAD and bronchiolitis, including
necrosis, oedema and inflammation. The most
obvious differences in histopathology include the
multinucleated giant cells and the intra-alveolar
fibrosis in SARS and the more fulminant necrotizing
and hemorrhagic pneumonia in H5N1 influenza.
However, there are many differences in the outcome
of disease after infection with different influenza vi-
ruses.
When evaluating the relationship between the pa-
thology and the pathogenesis of SARS and influenza
in the alveoli, certain virus-specific and host-specific
factors are important (Table 4). SARS and influenza
show a similar character of lesions, typified by necrosis
and inflammation. Firstly, the necrosis that is seen in
the lungs with both SARS and influenza can in part
be explained by a direct cytopathic effect or apoptotic
mechanisms. These mechanisms lead to damage of
epithelial cells, increased permeability of the alveolar
epithelium, damage of endothelial cells and subse-
quent oedema and haemorrhage, followed by forma-
tion of hyaline membranes (Berthiaume and
Matthay, 2007). Secondly, the necrosis and inflam-
mation in SARS and influenza can additionally be
attributed to the dysregulation of cytokine and che-
mokine production. Dysregulation of cytokines and
chemokines in SARS-CoV and H5N1 virus infectioncorrelates with high viral loads in pharyngeal swabs
and more severe pathological changes in severe or
fatal cases (de Jong et al., 2006; Cameron et al.,
2007; de Lang et al., 2007). Proinflammatory
cytokines such as IL-6 and IL-8, IP-10 and MCP-1
attract immune cells that constitute the inflammatory
infiltrate, which leads to even more production of cy-
tokines and chemokines (Theron et al., 2005;
Berthiaume and Matthay, 2007; Thiel and Weber,
2008). Together with the activation of oxidative
stress mechanisms that are induced by the up-
regulated cytokines, there is further cellular damage
and inflammation resulting in DAD (Tsushima
et al., 2009). Additionally, the infiltration of neutro-
phils results in a release of lytic enzymes that cause
further necrosis of epithelial cells and the infiltration
of cytotoxic T cells that results in necrosis of infected
epithelial cells.
The site of the lesions caused by SARS-CoV and
influenza virus is related to the receptors, and
although each virus uses different receptors, the role
of the receptors in the development of disease is
crucial in both infections. For infections with SARS-
CoV and influenza viruses, there is a correlation be-
tween the distributions of the receptor, the tropism
of the virus and the associated lesions (Tables 1 and
2). However, not all differences in the pathology be-
tween various animal species can be explained by
the differences in receptor distribution (Tables 3
and 4). This implies that other receptors and factors
also play a role in the attachment, replication, infec-
tiousness and virulence of both viruses (Lau and
Peiris, 2005; Nicholls et al., 2007).
There are two pathological features that are
remarkable in both SARS-CoV and influenza virus
infections: pulmonary fibrosis and tracheobroncho-
adenitis. First, in severe human cases of both SARS
and influenza there is marked loss of alveolar epithe-
lial lining, which may lead to re-epithelialization and
recovery, to death or to pulmonary fibrosis. Late
stages of fatal human cases of SARS were character-
ized by intra-alveolar and intrabronchiolar fibrosis,
and in approximately 62% of non-fatal SARS cases
there was evidence for fibrosis in thin section
computed tomography (CT) 1 month later (Franks
et al., 2003). In contrast, interstitial fibrosis has been
described in only a few fatal cases of H5N1 influenza,
including in two case descriptions with radiological
follow-up showing fibrosis-related changes (To et al.,
2001; Antonio et al., 2003). For pH1N1 influenza,
pulmonary fibrosis was also seen in only a few cases
by follow-up CT and the fibrosis often disappeared af-
ter 1 month (Bai et al., 2011; Mineo et al., 2012). The
importance of the previously mentioned factors for
fibrosis in SARS is not clear. Unfortunately, fibrosis
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virus infection in laboratory animals. This may be ex-
plained in part by the less severe lesions and the early
time point at which the animals are killed. Therefore,
this phenomenon is difficult to study in animal
models. The reason for the severe fibrosis in fatal hu-
man cases of SARS remains unclear and needs further
investigation. Secondly, tracheobronchoadenitis was
demonstrated in SARS-CoV infection in cats and
young macaques (van den Brand et al., 2008; Smits
et al., 2010) and in pH1N1 virus infection in ferrets
and was clearly associated with expression of virus
antigen (van den Brand et al., 2012a). This finding
has potentially important implications for the excre-
tion of those viruses. Excretion of virus might increase
due to infection of the tracheobronchial submucosal
glands and a diminished efficient defence by the mu-
cociliary system, and virus secreted by these glands
into the trachea and bronchi is more likely to be
expectorated than virus produced lower in the respi-
ratory tract.
Ageing is an important host factor associated with
increased morbidity and mortality from infections
with SARS-CoV and human seasonal influenza virus
(Meyer, 2001; Peiris et al., 2004a). This phenomenon
is also seen in a variety of other viral infections, such as
West Nile virus and norovirus infections, probably
because the elderly respond poorly to new antigens
compared with younger people due to
immunosenescence (Plackett et al., 2004; Licastro
et al., 2005; Meyer, 2005; Murasko and Jiang, 2005;
Salvioli et al., 2006). Immunosenescence is a
multifactorial process that is associated with thymic
involution, chronic antigen stimulation due to
persistent infections, signal transduction changes in
immune cells and proteineenergy malnutrition
(Fulop et al., 2005). Although all components of im-
munity are affected with ageing, the T cells are the
most susceptible and the increased susceptibility to
lower respiratory tract viral infections is particularly
related to defective T cell responses (Fulop et al.,
2005; Holt et al., 2005; Johnston, 2007).
Additionally, advanced age causes a general
increase in the levels of proinflammatory cytokines
in plasma, resulting in an age-related increase of
inflammation (Salvioli et al., 2006). Increased
amounts of proinflammatory cytokines, such as IL-
1b and IL-8, were produced upon stimulation of leu-
cocytes in the elderly, while induction of antiviral
type I IFNs was decreased compared with young
adults (Rink et al., 1998; Yoon et al., 2004; Kong
et al., 2008). Moreover, ageing results in less
protection against the oxidative stress that is
induced by virus infections and overreacting proin-
flammatory responses (Chung et al., 2006).Other factors related to the severity of disease in
SARS, seasonal influenza and pH1N1 infection are
pre-existing co-morbidities (e.g. diabetes mellitus
and cardiopulmonary disease), pregnancy and sex.
Pre-existing co-morbidities and pregnancy are associ-
ated predominantly with suppression of the immune
response, as is seen in older patients. In SARS, male
sex is correlated with more severe disease, while in
H5N1 infection females appear to have a worse
outcome than males, although not significantly
(Table 4) (Karlberg et al., 2004; Louie et al., 2011;
WHO, 2012). Interestingly, a sex difference in the
pathology of immune responses after viral infection
is suggested, since influenza virus infection of mice
results in greater neutrophil influx and more severe
lesions in females than in males (Karnam et al., 2012).
When comparing the influenza virus infections in
man, it is remarkable that H5N1 appears more likely
to spread to extrarespiratory tissues than seasonal
influenza virus (de Jong et al., 2006). In patients in-
fected with H5N1, diarrhoea was associated with the
detection of H5N1 RNA in faeces; it was suggested
that the virus may infect the gastrointestinal tract
directly or after subsequent dissemination via blood,
since H5N1 RNA was also detected in plasma (Beigel
et al., 2005; Uiprasertkul et al., 2005; Chutinimitkul
et al., 2006; de Jong et al., 2006). The hypothesis that
H5N1 could enter the human host via the
gastrointestinal tract is supported by the results of
experimental H5N1 infections in cats. Intestinal
H5N1 inoculation resulted in viral replication in the
capillary endothelium of the intestinal mucosa, which
was not seen in cats infected intratracheally
(Rimmelzwaan et al., 2006; Reperant et al., 2012).
Like H5N1 influenza, SARS in man is a respiratory
disease with extrarespiratory virus dissemination, as
demonstrated by antigen expression in several organs
and excretion of virus via respiratory secretions, stool,
urine and possibly sweat (Ding et al., 2004; Farcas
et al., 2005). Additionally, diarrhoea was seen in
SARS, with active viral replication in enterocytes but
minimal disruption of the intestinal architecture or
cellular infiltration. Up-regulation of the potent
immunosuppressive cytokine TGF-b (Cheng et al.,
2004) and an anti-apoptotic host cellular response in
the intestinal epithelial cells (Peiris et al., 2004a) may
be a cause for the diarrhoea. Spread to other extrares-
piratory tissues, such as the CNS, has been noted in
H5N1 infection of mammals such as mice, ferrets and
felids (Lipatov et al., 2003; Tanaka et al., 2003;
Keawcharoen et al., 2004), but has been recorded
rarely in human H5N1 infections (Morishima et al.,
2002; Sugaya, 2002; de Jong et al., 2005; Gu et al.,
2007). For SARS in man, no involvement of the
CNS has been seen.
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Points to Consider when Using Animal Models
SARS-CoV and influenza virus infections in experi-
mental animals demonstrate different pathways that
result in similar disease overall, which canbe compared
with the situation in fatal human cases (Tables 3 and
4). Samples taken from fatal human cases of SARS-
CoV and influenza virus infections often do not repre-
sent the full range of the different temporal stages of a
disease. Instead, they are more likely to represent
late-stage disease. In addition, the lesions caused by
the viral infection may be complicated by lesions
caused by clinical treatments and concurrent pre-
existing disease. Therefore, to be able to study the
course of the disease caused by these viruses, good ani-
malmodels are necessary for SARS-CoVand influenza
virus infections in man. Good animal models for SARS
and influenza inman should ideally show virus replica-
tion dynamics, clinical illness and pathological changes
that resemble those of human cases. The choice and
design of an animal model used in an experiment is
crucial for the outcome of the investigation and should
be considered carefully. Time course experiments pro-
vide information about the temporal and spatial dy-
namics that help to design such animal models,
including which time points and which samples are
best to gain the most useful information (van den
Brand et al., 2012a). Not only the best time points
and analyses of the most informative samples should
be considered carefully, but also the animal species,
the inoculation route and the age of the animals are
important, as is shown by studies of H5N1 influenza
in ferrets and of SARS in aged mice and macaques
(Rockx et al., 2009; Smits et al., 2010; Bodewes et al.,
2011). Taken together, animal models should be
designed specifically to address the aspect of SARS or
influenza in man that one is interested in, since no
one animal model can hope to address all the
variation that is inherent in these viral diseases.
Although current animal models do not fully mimic
the disease in fatal human cases of SARS, they can be
useful in pathogenesis and vaccination studies. For
pathogenesis studies, SARS-CoV need not cause mor-
tality in the animalmodel, since the vastmajority of hu-
man SARS cases are not fatal. For vaccination studies,
virus replication, virus excretion, antibody titres and
pathology scores are useful parameters for assessing
the level of protection against infection and disease.
In designing animal models for SARS, important
factors are the species and age of the laboratory ani-
mal used. Non-human primates, especially aged cyn-
omolgusmacaques andAGMs,most closely reflect the
pathology in fatal human SARS by demonstratingtypical pathological features such as hyaline mem-
branes and syncytial cells on SARS-CoV infection
(Smits et al., 2011). However, the severity of the clin-
ical signs and lesions, level of mortality and extent of
antigen expression in non-human primates is less
(Table 1) (Nicholls et al., 2006). The variation in path-
ological changes and cytokine profiles among different
non-human primate species, as well as among age
groups within each species, may reflect the variation
in severity of disease among people. For example,
the mild degree of pneumonia in SARS-CoV-
infected young-adult cynomolgus macaques may
resemble the milder cases of SARS in man (Kuiken
et al., 2004; Qin et al., 2005; Lawler et al., 2006;
Smits et al., 2010). While aged cynomolgus
macaques are good animal models for pathogenesis
studies, vaccination studies and intervention studies
of fatal SARS in man, large disadvantages are
ethical, cost-related and housing problems. Ferrets in-
fected with SARS-CoV only partly resemble fatal hu-
man SARS in terms of clinical illness, mortality and
typical histopathological features (Table 1) (van den
Brand et al., 2008). Moreover, methods for measuring
gene expression profiles of ferrets are not yet fully
developed. Nevertheless, ferrets can be used for path-
ogenesis and vaccination studies because they show
SARS-CoV-associated pulmonary lesions and
develop humoral immunity associated with reduced
virus replication on vaccination. Cats infected with
SARS-CoV show fewer similarities with the human
situation and have greater ethical, cost-related and
housing problems. Therefore, they are used less as an-
imal models for human SARS (van den Brand et al.,
2008). Although not discussed here, the use of aged
BALB/c mice as an animal model for fatal human
SARSmay be an alternative, since there aremany dif-
ficulties in the use of aged macaques (Subbarao and
Roberts, 2006). Recombinant zoonotic and early
phase SARS-CoV infection of these mice results in
clinical signs, virus replication, pulmonary lesions
and associated virus antigen expression in type II-
resembling pneumocytes, bronchiolar and bronchial
epithelial cells that partly resemble the features seen
in fatal human SARS (Rockx et al., 2009). Therefore,
aged BALB/cmicemay be used for pathogenesis, anti-
viral and vaccination studies. A disadvantage may be
age-related disease or mortality not related to SARS-
CoV infection, which may influence the results.
In designing animal models for influenza, an impor-
tant factor is the route of inoculation, because it can
markedly affect the outcome of infection. Therefore,
route of inoculation often depends on the purpose of
the experiment. Transmission studies (at least in fer-
rets) may well use intranasal inoculation, which
104 J.M.A. van den Brand et al.favours replication in the nose rather than in the lungs.
This may correlate with virus excretion from the nose
andminor pulmonary lesions. Additionally, intranasal
inoculation in ferrets results in encephalitis, sometimes
without pneumonia (Bodewes et al., 2011), and there-
fore this is not a good route for inducing viral pneu-
monia. In contrast, intratracheal inoculation favours
replication in the lungs and ismore likely to result in se-
vere pneumonia, whichmakes this route of inoculation
useful for pathogenesis and vaccination studies for viral
pneumonia (van den Brand et al., 2010a).
Another important factor in designing an animal
model for influenza, as in SARS, is the species of
laboratory animal used. In cynomolgus macaques,
the outcome of infection differs markedly according
to the influenza virus used (Table 2) (Herfst et al.,
2010). Therefore, cynomolgus macaques are prob-
ably not the best species to use for pathogenesis
studies of fatal human disease from pH1N1 or
seasonal influenza virus infections. However,
because these viruses do replicate and cause virus-
associated lesions, cynomolgus macaques may be
useful for vaccination studies. In contrast, cynomol-
gus macaques infected with H5N1 show similar fea-
tures as fatal human H5N1 infection and therefore
can be used for pathogenesis, vaccination or thera-
peutics studies of H5N1 infection. Ferrets infected
with different influenza viruses show similar virus
replication dynamics, clinical illness, virus associ-
ated pathological changes and virus attachment
patterns as in man (Table 2), and therefore are
often used in animal models for various purposes.
Cats infected with H5N1 show similar pathology
of the respiratory tract, but additionally demon-
strate a more widespread systemic infection than
is seen in human cases. The virus antigen expres-
sion and virus attachment patterns in cats show dif-
ferences and similarities similar to the case in
ferrets. The systemic dissemination makes the cat
less useful for animal models of fatal human
H5N1 pneumonia or vaccination studies, since ex-
trarespiratory replication and inflammation can in-
fluence the results. Taken together, ferrets are a
good animal species to model fatal human influ-
enza; however, there are species differences between
man and ferrets, as well as differences between lab-
oratory and field conditions. Therefore, the conclu-
sions from ferret studies need thorough assessment
to be able to make full use of the results without
over-interpreting them.Recently-emerging Respiratory Viruses
The importance of thorough pathological examina-
tion and development of good animal models for se-vere disease from respiratory viruses is demonstrated
by the occurrence of recently-emerging viruses.
Only very recently and ongoing there are two out-
breaks of mild to severe respiratory illness with clin-
ical disease and pathological features comparable to
those in SARS-CoV and influenza viruses. In 2012,
there was an outbreak ofMiddle East respiratory syn-
drome (MERS) caused by the MERS-CoV in the
Middle East (van Boheemen et al., 2012). People
from Europe and Africa have acquired MERS-CoV
while travelling or staying in the Middle East, with
to date more than 139 cases with 60 fatal cases
(CDC, 2013). Additionally, there is limited human
to human transmission, as is demonstrated by reports
on 12 clusters, which occurred among close contacts
or in healthcare settings (CDC, 2013). Only one au-
topsy of a MERS patient is described so far and this
revealed severe DAD comparable with that seen in
SARS (unpublished data). Experiments with rhesus
and cynomolgus macaques and ferrets have demon-
strated that the character of the lesions is comparable
with those in macaques infected with SARS-CoV
(unpublished data) (Munster et al., 2013). As in
SARS-CoV infection in cynomolgus macaques, the
severity and extent of the lesions in macaques is less
than seen in human patients. Ferrets did not show a
productive infection in contrast to what is seen in fer-
rets infected with SARS-CoV. As in SARS, a good
animal model for severe pneumonia in human
MERS has not yet been established and more
research needs to be done.
At the beginning of 2013 an outbreak of LPAI virus
H7N9 caused severe and fatal pneumonia in people in
China. To date there are 135 reported cases, including
45 fatal cases (WHO, 2013). The first experiments
with ferrets show disease more comparable with that
of HPAI H5N1 in ferrets, so ferrets may be a good an-
imal model for H7N9 infection in man (Belser et al.,
2013; Richard et al., 2013; Watanabe et al., 2013).
The outbreaks of MERS and H7N9 demonstrate the
need for good animal models for severe pneumonia
in people infected with respiratory viruses. These
models are needed to develop preventive and
therapeutic measures and to gain insight into the
pathogenesis of such virus infections.Future Perspectives
Many steps in the development of severe and fatal dis-
ease after SARS-CoV and influenza virus infection
remain unknown. In the future, new or improved
techniques such as genomics, proteomics and stem
cell research may improve our knowledge of disease
and recovery after disease and may be helpful in the
development of effective interventions against severe
Animal Models of SARS and Influenza 105disease. For seasonal influenza, aged animals may be
an alternative for the inoculation of high doses of virus
in ferrets as is seen in SARS-CoV infection in aged
macaques and mice and recently for pH1N1 in aged
macaques (Rockx et al., 2009; Smits et al., 2010;
Josset et al., 2012). For all respiratory viruses that
cause severe damage of alveolar and bronchiolar
epithelium, treatment with stem cells may prevent
severely ill patients from dying (Kumar et al., 2011).
For both SARS and influenza, experiments with im-
munosuppressed animals (e.g. by using methods
that are also used in organ transplantation) may
help find better animal models that more accurately
mimic the clinical situation (van der Vries et al.,
2013).
Animal models are important not only for research
on the known virus strains and subtypes of SARS-
CoV and influenza A viruses. All kinds of viruses are
ubiquitous among (wild) animals (Kuiken et al.,
2005; van den Brand et al., 2012b); for example, bats
harbour viruses that are similar to the epidemic
strain of SARS-CoV and MERS-CoV (Li et al.,
2005b; van Boheemen et al., 2012). Such viruses may
be the source of future emerging infections. The
travelling behaviour of people, as well as transport of
animals and animal products, can result in easy
spread of such infections, as was seen in the recent
SARS and pH1N1 pandemics.
In conclusion, at the time of an outbreak of severe
fatal disease in man, all steps from the discovery of
the cause of the disease to the development and testing
of appropriate therapeutic and preventive strategies
should be carefully considered and pursued. These ac-
tions should take into account all of the lessons learned
from previous outbreaks and be performed as a joint
effort with all relevant disciplines, as part of the
concept of ‘One Health’, to meet the many serious
challenges to the health of people, domestic animals
and wildlife and to the integrity of ecosystems.Funding
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